Browse > Article
http://dx.doi.org/10.4062/biomolther.2020.013

Dasatinib Inhibits Lyn and Fyn Src-Family Kinases in Mast Cells to Suppress Type I Hypersensitivity in Mice  

Lee, Dajeong (Department of Immunology, College of Medicine, Konkuk University)
Park, Young Hwan (Department of Immunology, College of Medicine, Konkuk University)
Lee, Ji Eon (Department of Immunology, College of Medicine, Konkuk University)
Kim, Hyuk Soon (Department of Immunology, College of Medicine, Konkuk University)
Min, Keun Young (Department of Immunology, College of Medicine, Konkuk University)
Jo, Min Geun (Department of Immunology, College of Medicine, Konkuk University)
Kim, Hyung Sik (Division of Toxicology, College of Pharmacy, Sungkyunkwan University)
Choi, Wahn Soo (Department of Immunology, College of Medicine, Konkuk University)
Kim, Young Mi (College of Pharmacy, Duksung Women's University)
Publication Information
Biomolecules & Therapeutics / v.28, no.5, 2020 , pp. 456-464 More about this Journal
Abstract
Mast cells (MCs) are systemically distributed and secrete several allergic mediators such as histamine and leukotrienes to cause type I hypersensitivity. Dasatinib is a type of anti-cancer agent and it has also been reported to inhibit human basophils. However, dasatinib has not been reported for its inhibitory effects on MCs or type I hypersensitivity in mice. In this study, we examined the inhibitory effect of dasatinib on MCs and MC-mediated allergic response in vitro and in vivo. In vitro, dasatinib inhibited the degranulation of MCs by antigen stimulation in a dose-dependent manner (IC50, ~34 nM for RBL-2H3 cells; ~52 nM for BMMCs) without any cytotoxicity. It also suppressed the secretion of inflammatory cytokines IL-4 and TNF-α by antigen stimulation. Furthermore, dasatinib inhibited MC-mediated passive cutaneous anaphylaxis (PCA) in mice (ED50, ~29 mg/kg). Notably, dasatinib significantly suppressed the degranulation of MCs in the ear tissue. As the mechanism of its effect, dasatinib inhibited the activation of Syk and Syk-mediated downstream signaling proteins, LAT, PLCγ1, and three typical MAP kinases (Erk1/2, JNK, and p38), which are essential for the activation of MCs. Interestingly, in vitro tyrosine kinase assay, dasatinib directly inhibited the activities of Lyn and Fyn, the upstream tyrosine kinases of Syk in MCs. Taken together, dasatinib suppresses MCs and PCA in vitro and in vivo through the inhibition of Lyn and Fyn Src-family kinases. Therefore, we suggest the possibility of repositioning the anti-cancer drug dasatinib as a treatment for various MC-mediated type I hypersensitive diseases.
Keywords
Dasatinib; Mast cell; Type I hypersensitivity; Lyn; Fyn;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Shah, N. P., Kasap, C., Weier, C., Balbas, M., Nicoll, J. M., Bleickardt, E., Nicaise, C. and Sawyers, C. L. (2008) Transient potent BCRABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 14, 485-493.   DOI
2 Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J. and Sawyers, C. L. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117-125.   DOI
3 Siraganian, R. P., de Castro, R. O., Barbu, E. A. and Zhang, J. (2010) Mast cell signaling: the role of protein tyrosine kinase Syk, its activation and screening methods for new pathway participants. FEBS Lett. 584, 4933-4940.   DOI
4 Wang, W., Zhou, Q., Liu, L. and Zou, K. (2012) Anti-allergic activity of emodin on IgE-mediated activation in RBL-2H3 cells. Pharmacol. Rep. 64, 1216-1222.   DOI
5 Warrington, R., Silviu-Dan, F. and Wong, T. (2018) Drug allergy. Allergy Asthma Clin. Immunol. 14, 60.   DOI
6 Wedemeyer, J., Tsai, M. and Galli, S. J. (2000) Roles of mast cells and basophils in innate and acquired immunity. Curr. Opin. Immunol. 12, 624-631.   DOI
7 Kim, J. D., Kim, D. K., Kim, H. S., Kim, A. R., Kim, B., Her, E., Park, K. H., Kim, H. S., Kim, Y. M. and Choi, W. S. (2013) Morusbombycis extract suppresses mast cell activation and IgE-mediated allergic reaction in mice. J. Ethnopharmacol. 146, 287-293.   DOI
8 Kneidinger, M., Schmidt, U., Rix, U., Gleixner, K. V., Vales, A., Baumgartner, C., Lupinek, C., Weghofer, M., Bennett, K. L., Herrmann, H., Schebesta, A., Thomas, W. R., Vrtala, S., Valenta, R., Lee, F. Y., Ellmeier, W., Superti-Furga, G. and Valent, P. (2008) The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood 111, 3097-3107.   DOI
9 Kim, J. W., Lee, J. H., Hwang, B. Y., Mun, S. H., Ko, N. Y., Kim, D. K., Kim, B., Kim, H. S., Kim, Y. M. and Choi, W. S. (2009) Morin inhibits Fyn kinase in mast cells and IgE-mediated type I hypersensitivity response in vivo. Biochem. Pharmacol. 77, 1506-1512.   DOI
10 Kitanaka, S., Nakayama, T., Shibano, T., Ohkoshi, E. and Takido, M. (1998) Antiallergic agent from natural sources. Structures and inhibitory effect of histamine release of naphthopyrone glycosides from seeds of Cassia obtusifolia L. Chem. Pharm. Bull. (Tokyo) 46, 1650-1652.   DOI
11 Krystel-Whittemore, M., Dileepan, K. N. and Wood, J. G. (2016) Mast cell: a multi-functional master cell. Front. Immunol. 6, 620.   DOI
12 Lee, Y. S., Kang, O. H., Choi, J. G., Oh, Y. C., Keum, J. H., Kim, S. B., Jeong, G. S., Kim, Y. C., Shin, D. W. and Kwon, D. Y. (2010) Synergistic effect of emodin in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus. 48, 1285-1290.   DOI
13 Lin, S., Cicala, C., Scharenberg, A. M. and Kinet, J. P. (1996) The $Fc{\varepsilon}RI{\beta}$ subunit functions as an amplifier of $Fc{\varepsilon}RI{\gamma}$-mediated cell activation signals. Cell 85, 985-995.   DOI
14 Akin, C. (2017) Mast cell activation syndromes. J. Allergy Clin. Immunol. 140, 349-355.   DOI
15 Weng, Z., Patel A. B., Panagiotidou, S. and Theoharides, T. C. (2015) The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. J. Allergy Clin. Immunol. 135, 1044-1052.   DOI
16 Xiao, J., Xu, M., Hou, T., Huang, Y., Yang, C. and Li, J. (2015) Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling. Mol. Med. Rep. 12, 3249-3256.   DOI
17 Yamaguchi, M., Sayama, K., Yano, K., Lantz, C. S., Noben-Trauth, N., Ra, C., Costa, J. J. and Galli, S. J. (1999) IgE enhances Fc epsilon receptor I expression and IgE-dependent release of histamine and lipid mediators from human umbilical cord blood-derived mast cells: synergistic effect of IL-4 and IgE on human mast cell Fc epsilon receptor I expression and mediator release. J. Immunol. 162, 5455-5465.
18 Begin, P. and Nadeau, K. C. (2014) Epigenetic regulation of asthma and allergic disease. Allergy Asthma Clin. Immunol. 10, 27.   DOI
19 Qiao, H., Andrade, M. V., Lisboa, F. A., Morgan, K. and Beaven, M. A. (2006) $Fc{\varepsilon}RI$ and toll-like receptors mediate synergistic signals to markedly augment production of inflammatory cytokines in murine mast cells. Blood 107, 610-618.   DOI
20 Aketani, S., Teshima, R., Umezzawa, Y. and Sawada, J. (2001) Correlation between cytosolic calcium concentration and degranulation in RBL-2H3 cells in the presence of various concentrations of antigen-specific IgEs. Immunol. Lett. 75, 185-189.   DOI
21 Atallah, E., Kantarjian, H. and Cortes, J. (2007) Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors. Clin. Lymphoma Myeloma 7, S105-S112.   DOI
22 Barnes, P. J. (1999) Therapeutic strategies for allergic diseases. Nature 402, 31-38.
23 Minai-Fleminger, Y. and Levi-Schaffer, F. (2009) Mast cells and eosinophils: the two key effector cells in allergic inflammation. Inflamm. Res. 58, 631-638.   DOI
24 Bradding, P., Walls, A. F. and Holgate, S. T. (2006) The role of the mast cell in the pathophysiology of asthma. J. Allergy Clin. Immunol. 117, 1277-1284.   DOI
25 Lindner, I., Meier, C., Url, A., Unger, H., Grassauer, A., Prieschl-Grassauer, E. and Doerfler, P. (2010) Beta-escin has potent anti-allergic efficacy and reduces allergic airway inflammation. BMC Immunol. 11, 24.   DOI
26 Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A., Das, J., Doweyko, A. M., Fairchild, C., Hunt, J. T., Inigo, I., Johnston, K., Kamath, A., Kan, D., Klei, H., Marathe, P., Pang, S., Peterson, R., Pitt, S., Schieven, G. L., Schmidt, R. J., Tokarski, J., Wen, M. L., Wityak, J. and Borzilleri, R. M. (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658-6661.   DOI
27 Mastuda, H., Morikawa, T., Ueda, K., Managi, H. and Yoshikawa, M. (2002) Structural requirements of flavonoids for inhibition of antigen-Induced degranulation, $TNF-{\alpha}$ and IL-4 production from RBL-2H3 cells. Bioorg. Med. Chem. 10, 3123-3128.   DOI
28 Masuda, E. S. and Schmitz, J. (2008) Syk inhibitors as treatment for allergic rhinitis. Pulm. Pharmacol. Ther. 21, 461-467.   DOI
29 Montani, D., Bergot, E., Gunther, S., Savale, L., Bergeron, A., Bourdin, A., Bouvaist, H., Canuet, M., Pison, C., Macro, M., Poubeau, P., Girerd, B., Natali, D., Guignabert, C., Perros, F., O'Callaghan, D. S., Jais, X., Tubert-Bitter, P., Zalcman, G., Sitbon, O., Simonneau, G. and Humbert, M. (2012) Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125, 2128-2137.   DOI
30 Mitre, E. and Nutman, T. B. (2006) Basophils, basophilia and helminth infections. Chem. Immunol. Allergy 90, 141-156.   DOI
31 El-Agamy, D. S. (2012) Targeting c-kit in the therapy of mast cell disorders: current update. Eur. J. Pharmacol. 690, 1-3.   DOI
32 Bruhns, P., Fremont, S. and Daeron, M. (2005) Regulation of allergy by Fc receptors. Curr. Opin. Immunol. 17, 662-669.   DOI
33 Charles, N., Watford, W. T., Ramos, H. L., Hellman, L., Oettgen, H. C., Gomez, G., Ryan, J. J., O'Shea, J. J. and Rivera, J. (2009) Lyn kinase controls basophil GATA-3 transcription factor expression and induction of Th2 cell differentiation. Immunity 30, 533-543.   DOI
34 Draber, P., Halova, I., Polakovicova, I. and Kawakami, T. (2016) Signal transduction and chemotaxis in mast cells. Eur. J. Pharmacol. 778, 11-23.   DOI
35 Feinberg, J. G. (1961) Pinnal anaphylaxis: an additional anaphyiactic site. Nature 191, 712.
36 Galli, S. J., Kalesnikoff, J., Grimbaldeston, M. A., Piliponsky, A. M., Williams, C. M. and Tsai, M. (2005) Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu. Rev. Immunol. 23, 749-786.   DOI
37 Geha, R. S., Jabara, H. H. and Brodeur, S. R. (2003) The regulation of immunoglobulin E class-switch recombination. Nat. Rev. Immunol. 3, 721-732.   DOI
38 Murakami, M. and Kudo, I. (2001) Diversity and regulatory functions of mammalian secretory phospholipase A2s. Adv. Immunol. 77, 163-194.
39 Gomez, G. (2019) Current strategies to inhibit high affinity $Fc{\varepsilon}RI$-mediated signaling for the treatment of allergic disease. Front. Immunol. 10, 175.   DOI
40 Heuchel, R., Berg, A., Tallquist, M., Ahlen, K., Reed, R. K., Rubin, K., Claesson-Welsh, L., Heldin, C. H. and Soriano, P. (1999) Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3' kinase signaling. Proc. Natl. Acad. Sci. U.S.A. 96, 11410-11415.   DOI
41 Nam, S. T., Park, Y. H., Kim, H. W., Kim, H. S., Lee, D., Lee, M. B., Kim, Y. M. and Choi, W. S. (2017) Suppression of IgE-mediated mast cell activation and mouse anaphylaxis via inhibition of Syk activation by 8-formyl-7-hydroxy-4-methylcoumarin, $4{\mu}8C$. Toxicol. Appl. Pharmacol. 332, 25-31.   DOI
42 Ovary, Z. (1958) Passive cutaneous anaphylaxis in the mouse. J. Immunol. 81, 355-357.
43 Park, Y. H., Kim, D. K., Kim, H. W., Kim, H. S., Lee, D., Lee, M. B., Min, K. Y., Koo, J., Kim, S. J., Kang, C., Kim, Y. M., Kim, H. S. and Choi, W. S. (2018) Repositioning of anti-cancer drug candidate, AZD7762, to an anti-allergic drug suppressing IgE-mediated mast cells and allergic responses via the inhibition of Lyn and Fyn. Biochem. Pharmacol. 154, 270-277.   DOI
44 Park, Y. H., Kim, H. W., Kim, H. S., Nam, S. T., Lee, D., Lee, M. B., Min, K. Y., Koo, J., Kim, S. J., Kim, Y. M., Kim, H. S. and Choi, W. S. (2019) An anti-cancer drug candidate CYC116 suppresses type I hypersensitive immune responses through the inhibition of Fyn kinase in mast cells. Biomol. Ther. (Seoul) 27, 311-317.   DOI
45 Horny, H. P., Sotlar, K. and Valent, P. (2007) Mastocytosis: state of the art. Pathobiology 74, 121-132.   DOI
46 Parravicini, V., Gadina, M., Kovarova, M., Odom, S., Gonzalez-Espinosa, C., Furumoto, Y., Saitoh, S., Samelson, L. E., O'Shea, J. J. and Rivera, J. (2002) Fyn kinase initiates complementary signals required for IgE-dependent mast cell degranulation. Nat. Immunol. 3, 741-748.   DOI
47 Randall, K. L. and Hawkins, C. A. (2018) Antihistamines and allergy. Aust. Prescr. 41, 41-45.   DOI
48 Rivera, J. (2002) Molecular adapters in $Fc{\varepsilon}RI$ signaling and the allergic response. Curr. Opin. Immunol. 14, 688-693.   DOI
49 Hide, I., Toriu, N., Nuibe, T., Inoue, A., Hide, M., Yamamoto, S. and Nakata, Y. (1997) Suppression of TNF-alpha secretion by azelastine in a rat mast (RBL-2H3) cell line: evidence for differential regulation of TNF-alpha release, transcription, and degranulation. J. Immunol. 159, 2932-2940.
50 Hoffmann, A., Jamin, A., Foetisch, K., May, S., Aulepp, H., Haustein, D. and Vieths, S. (1999) Determination of the allergenic activity of birch pollen and apple prick test solutions by measurement of $\beta$-hexosaminidase release from RBL-2H3 cells. Comparison with classical methods in allergen standardization. Allergy 54, 446-454.   DOI
51 Kambayashi, T. and Koretzky, G. A. (2007) Proximal signaling events in Fc epsilon RI-mediated mast cell activation. J. Allergy Clin. Immunol. 119, 544-552.   DOI
52 Inagaki, N. and Nagai, H. (2009) Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment: mouse models for the development of remedies for human allergic dermatitis. J. Pharmacol. Sci. 110, 251-259.   DOI
53 Iqbal, N. and Iqbal, N. (2014) Imatinib: a breakthrough of targeted therapy in cancer. Chemother. Res. Pract. 2014, 357027.
54 Kagan, R. S. (2003) Food allergy: an overview. Environ. Health Perspect. 111, 223-225.   DOI
55 Kantarjian, H., Jabbour, E., Grimley, J. and Kirkpatrick, P. (2006) Dasatinib. Nat. Rev. Drug Discov. 5, 717-718.   DOI
56 Kay, A. B. (2001) Allergy allergic diseases. First of two parts. N. Engl. J. Med. 344, 30-37.   DOI
57 Schroeder, J. T., MacGlashan, D.W., Jr. and Lichtenstein, L. M. (2001) Human basophils: mediator release and cytokine production. Adv. Immunol. 77, 93-122.
58 Rivera, J., Cordero, J. R., Furumoto, Y., Luciano-Montalvo, C., Gonzalez-Espinosa, C., Kovarova, M., Odom, S. and Parravicini, V. (2002) Macromolecular protein signaling complexes and mast cell responses: a view of the organization of IgE-dependent mast cell signaling. Mol. Immunol. 38, 1253-1258.   DOI